New and improved tuberculosis diagnostics: Evidence, policy, practice, and impact

Current Opinion in Pulmonary Medicine

Volumn 16, Issue 3, 2010, Pages 271-284

  Pai, Madhukar ^a   Minion, Jessica ^a   Steingart, Karen ^b   Ramsay, Andrew ^c  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

Diagnostics; Evidence; Impact; Policy; Tuberculosis

Indexed keywords

ACCURACY; HEALTH CARE POLICY; HUMAN; MEDICAL PRACTICE; POINT OF CARE TESTING; PUBLIC HEALTH; REVIEW; SENSITIVITY AND SPECIFICITY; TUBERCULOSIS; TUBERCULOSIS CONTROL; WORLD HEALTH ORGANIZATION;

COMMUNICABLE DISEASE CONTROL; EVIDENCE-BASED MEDICINE; FEMALE; HEALTH POLICY; HUMANS; INCIDENCE; INTERNATIONAL COOPERATION; MALE; POLICY MAKING; PRACTICE GUIDELINES AS TOPIC; PROGRAM DEVELOPMENT; PROGRAM EVALUATION; RISK ASSESSMENT; TUBERCULOSIS; TUBERCULOSIS, PULMONARY; WORLD HEALTH; WORLD HEALTH ORGANIZATION;

EID: 77951091847     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e328338094f     Document Type: Review

References (78)

1. Pai M, Minion J, Sohn H, et al. Novel and improved technologies for tuberculosis diagnosis: progress and challenges. Clin Chest Med 2009; 30:701-716.
2. Perkins MD, Cunningham J. Facing the crisis: improving the diagnosis of tuberculosis in the HIV era. J Infect Dis 2007; 196 (Suppl 1):S15-S27.
3. World Health Organization & Stop TB Partnership. New laboratory diagnostic tools for tuberculosis control. Geneva: World Health Organization; 2008.
4. Pai M, O'Brien R. Newdiagnostics for latent and active tuberculosis: state of the art and future prospects. Semin Respir Crit Care Med 2008; 29:560-568.
5. Pai M, Ramsay A, O'Brien R. Comprehensive new resource for evidencebased TB diagnosis. Expert Rev Mol Diagn 2009; 9:637-639.
6. Pai M, Ramsay A, O'Brien R. Evidence-based tuberculosis diagnosis. PLoS Med 2008; 5:e156.
7. Steingart KR, Henry M, Ng V, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006; 6:570-581. (Pubitemid 44262344)
8. Steingart KR, Ng V, Henry M, et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis 2006; 6:664-674.
9. Mase SR, Ramsay A, Ng V, et al. Yield of serial sputum specimen examinations in the diagnosis of pulmonary tuberculosis: a systematic review. Int J Tuberc Lung Dis 2007; 11:485-495.
10. Greco S, Girardi E, Navarra S, Saltini C. The current evidence on diagnostic accuracy of commercial based nucleic acid amplification tests for the diagnosis of pulmonary tuberculosis. Thorax 2006; 61:783-790.
11. Ling DI, Flores LL, Riley LW, Pai M. Commercial nucleic-acid amplification tests for diagnosis of pulmonary tuberculosis in respiratory specimens: metaanalysis and meta-regression. PLoS One 2008; 3:e1536.
12. Dinnes J, Deeks J, Kunst H, et al. A systematic review of rapid diagnostic tests for the detection of tuberculosis infection. Health Technol Assess 2007; 11:1-196.
13. Pai M, Flores LL, Hubbard A, et al. Nucleic acid amplification tests in the diagnosis of tuberculous pleuritis: a systematic review and meta-analysis. BMC Infect Dis 2004; 4:6.
14. Pai M, Flores LL, Pai N, et al. Diagnostic accuracy of nucleic acid amplification tests for tuberculous meningitis: a systematic review and meta-analysis. Lancet Infect Dis 2003; 3:633-643.
15. Daley P, Thomas S, Pai M. Nucleic acid amplification tests for the diagnosis of tuberculous lymphadenitis: a systematic review. Int J Tuberc Lung Dis 2007; 11:1166-1176.
16. Steingart KR, Henry M, Laal S, et al. A systematic review of commercial serological antibody detection tests for the diagnosis of extra-pulmonary tuberculosis. Thorax 2007; 62:911-918. (Pubitemid 47598357)
17. Steingart KR, Henry M, Laal S, et al. Commercial serological antibody detection tests for the diagnosis of pulmonary tuberculosis: a systematic review. PLoS Med 2007; 4:e202.
18. Steingart KR, Dendukuri N, Henry M, et al. Performance of purified antigens for serodiagnosis of pulmonary tuberculosis: a meta-analysis. Clin Vaccine Immunol 2009; 16:260-276.
19. Greco S, Girardi E, Masciangelo R, et al. Adenosine deaminase and interferon gamma measurements for the diagnosis of tuberculous pleurisy: a metaanalysis. Int J Tuberc Lung Dis 2003; 7:777-786.
20. Liang QL, Shi HZ, Wang K, et al. Diagnostic accuracy of adenosine deaminase in tuberculous pleurisy: a meta-analysis. Respir Med 2008; 102:744-754.
21. Jiang J, Shi HZ, Liang QL. Diagnostic value of interferon-g in tuberculous pleurisy: a meta-analysis. Chest 2007; 131:1133-1141.
22. Kalantri S, Pai M, Pascopella L, et al. Bacteriophage-based tests for the detection of Mycobacterium tuberculosis in clinical specimens: a systematic review and meta-analysis. BMC Infect Dis 2005; 5:59.
23. Cruciani M, Scarparo C, Malena M, et al. Meta-analysis of BACTEC MGIT 960 and BACTEC 460 TB, with or without solid media, for detection of mycobacteria. J Clin Microbiol 2004; 42:2321-2325.
24. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and nontuberculous mycobacteria? Int J Tuberc Lung Dis 2006; 10:1192-1204.
25. Wang L, Turner MO, Elwood RK, et al. A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements. Thorax 2002; 57:804-809.
26. Pai M, Zwerling A, Menzies D. T-cell based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149:177-184.
27. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146:340-354.
28. Pai M, Riley LW, Colford JM Jr. Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review. Lancet Infect Dis 2004; 4:761-776.
29. van Zyl-Smit RN, Zwerling A, Dheda K, Pai M. Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. PLoS One 2009; 4:e8517.
30. Pai M, Kalantri S, Pascopella L, et al. Bacteriophage-based assays for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a meta-analysis. J Infect 2005; 51:175-187. (Pubitemid 41554824)
31. Minion J, Pai M. Bacteriophage assays for rifampin resistance detection in Mycobacterium tuberculosis: updated meta-analysis. Presented at the World Health Organization Expert Group Meeting on Non-commercial Culture Methods and Mycobacteriophage-based Assays for Rapid Screening of Patients at Risk of Drug-Resistant Tuberculosis. September 8-9, 2009, Geneva, Switzerland.
32. Ling DI, Zwerling A, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 2008; 32:1165-1174.
33. Morgan M, Kalantri S, Flores L, Pai M. A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. BMC Infect Dis 2005; 5:62.
34. Bwanga F, Hoffner S, Haile M, Joloba ML. Direct susceptibility testing for multi drug resistant tuberculosis: a meta-analysis. BMC Infect Dis 2009; 9:67.
35. Martin A, Portaels F, Palomino JC. Colorimetric redox-indicator methods for the rapid detection of multidrug resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 59: 175-183.
36. Martin A, Panaiotov S, Portaels F, et al. The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2008; 62:56-64.
37. Minion J, Leung E, Menzies D, Pai M. Microscopic-Observation Drug Susceptibility (MODS) and Thin Layer Agar (TLA) assays for the detection of drug resistant tuberculosis: a systematic review. Presented at the World Health Organization Expert Group Meeting on Non-commercial Culture Methods and Mycobacteriophage-based Assays for Rapid Screening of Patients at Risk of Drug-Resistant Tuberculosis. September 8-9, 2009, Geneva, Switzerland.
38. Pai M, O'Brien R. Tuberculosis diagnostics trials: do they lack methodological rigor? Expert Rev Mol Diagn 2006; 6:509-514.
39. Fontela PS, Pai NP, Schiller I, et al. Quality and reporting of diagnostic accuracy studies in TB, HIV and malaria: evaluation using QUADAS and STARD standards. PLoS One 2009; 4:e7753.
40. Banoo S, Bell D, Bossuyt P, et al. Evaluation of diagnostic tests for infectious diseases: general principles. Nat Rev Microbiol 2006; 4 (9 Suppl):S21-S31. (Pubitemid 44507645)
41. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Ann Intern Med 2003; 138:40-44.
42. Stop TB Partnership's New Diagnostics Working Group and World Health Organization. Pathways to better diagnostics for tuberculosis: a blueprint for the development of TB diagnostics. Geneva: World Health Organization; 2009.
43. Bossuyt PM, McCaffery K. Additional patient outcomes and pathways in evaluations of testing. Med Decis Making 2009; 29:E30-E38.
44. Lord SJ, Irwig L, Bossuyt PM. Using the principles of randomized controlled trial design to guide test evaluation. Med Decis Making 2009; 29:E1-E12.
45. Keeler E, Perkins MD, Small P, et al. Reducing the global burden of tuberculosis: the contribution of improved diagnostics. Nature 2006; 444 (Suppl 1): 49-57.
46. Abu-Raddad LJ, Sabatelli L, Achterberg JT, et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc Natl Acad Sci U S A 2009; 106:13980-13985.
47. Getahun H, Harrington M, O'Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resourceconstrained settings: informing urgent policy changes. Lancet 2007; 369: 2042-2049.
48. Marais BJ, Pai M. New approaches and emerging technologies in the diagnosis of childhood tuberculosis. Paediatr Respir Rev 2007; 8:124-133.
49. Barry CE 3rd, Boshoff HI, Dartois V, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009; 7:845-855.
50. Pai M. Spectrum of latent tuberculosis: existing tests cannot resolve the underlying phenotypes. Nat Rev Microbiol 2010 Jan 19 [Epub ahead of print].
51. World Health Organization. Moving research findings into newWHOpolicies. http://www.who.int/tb/dots/laboratory/policy/en/index4.html. Geneva: World Health Organization; 2008.
52. Leeflang MM, Deeks JJ, Gatsonis C, Bossuyt PM. Systematic reviews of diagnostic test accuracy. Ann Intern Med 2008; 149:889-897.
53. World Health Organization. The use of liquid medium for culture and DST. http://www.who.int/tb/dots/laboratory/policy/en/index3.html. Geneva: World Health Organization; 2007.
54. World Health Organization. Reduction of number of smears for the diagnosis of pulmonary TB [cited 27 January 2010]. http://www.who.int/tb/dots/ laboratory/ policy/en/index2.html
55. World Health Organization. Definition of a new sputum smear-positive TB case [cited 27 January 2010]. http://www.who.int/tb/dots/laboratory/policy/ en/index1.html
56. World Health Organization. Policy statement. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDRTB) [cited 27 January 2010]. http://www.who.int/tb/dots/laboratory/policy/ en/index4.html
57. World Health Organization. Report of the 9th Meeting of the Strategic and Technical Advisory Group on Tuberculosis (STAG-TB). Geneva: World Health Organization; 2009 http://www.who.int/tb/advisory-bodies/stag/en/ index.html
58. Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008; 336:924-926.
59. Oxman AD, Lavis JN, Fretheim A. Use of evidence inWHOrecommendations. Lancet 2007; 369:1883-1889.
60. Schunemann HJ, Oxman AD, Brozek J, et al. GRADE: assessing the quality of evidence for diagnostic recommendations. Evid Based Med 2008; 13:162-163.
61. World Health Organization. Guidelines for WHO Guidelines. Geneva: World Health Organization; 2003.
62. World Health Organization. WHO policy on TB infection control in healthcare facilities, congregate settings and households. Geneva: World Health Organization; 2010.
63. World Health Organization. Treatment of tuberculosis. 4th ed. Geneva: World Health Organization; 2009.
64. Schunemann HJ, Oxman AD, Brozek J, et al. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008; 336:1106-1110.
65. Brozek JL, Akl EA, Jaeschke R, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines: Part 2 of 3. The GRADE approach to grading quality of evidence about diagnostic tests and strategies. Allergy 2009; 64:1109-1116.
66. Kavanagh BP. The GRADE system for rating clinical guidelines. PLoS Med 2009; 6:e1000094.
67. Pai M. Guidelines on IGRAs: concordant or discordant? 2nd Global Symposium on IGRAs. Dubrovnik, Croatia; 2009.
68. Schunemann HJ, Osborne M, Moss J, et al. An official American Thoracic Society Policy statement: managing conflict of interest in professional societies. Am J Respir Crit Care Med 2009; 180:564-580.
69. Biesheuvel CJ, Grobbee DE, Moons KG. Distraction from randomization in diagnostic research. Ann Epidemiol 2006; 16:540-544.
70. Steingart KR, Ramsay A, Pai M. Commercial serological tests for the diagnosis of tuberculosis: do they work? Future Microbiol 2007; 2:355-359.
71. World Health Organization & UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases. Laboratory-based evaluation of 19 commercially-available rapid diagnostic tests for tuberculosis. Geneva: World Health Organization; 2008.
72. Pai M, McCulloch M, Enanoria W, Colford JM Jr. Systematic reviews of diagnostic test evaluations: what's behind the scenes? ACP J Club 2004; 141:A11-A13.
73. World Health Organization. New technologies for tuberculosis control: a framework for their adoption, introduction and implementation [WHO/HTM/ STB/2007.40]. Geneva: World Health Organization; 2007.
74. Stop TB Partnership Retooling Task Force. Engaging stakeholders for retooling TB control. Geneva: World Health Organization; 2008.
75. Stop TB Partnership Retooling Task Force. Checklist of key actions for the use of liquid culture and drug susceptibility testing. Geneva: World Health Organization; 2008.
76. Ridderhof JC, van Deun A, Kam KM, et al. Roles of laboratories and laboratory systems in effective tuberculosis programmes. Bull World Health Organ 2007; 85:354-359.
77. World Health Organization. Strategic approach to the strengthening of laboratory services for tuberculosis control: 2006-2009. Geneva: World Health Organization; 2006.
78. Yagui M, Perales MT, Asencios L, et al. Timely diagnosis of MDR-TB under program conditions: is rapid drug susceptibility testing sufficient? Int J Tuberc Lung Dis 2006; 10:838-843.